First Wave BioPharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From First Wave BioPharma, Inc.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 3: Global Headwinds
Headwinds of political instability, violent conflict, inflation and recession accompany us into 2023. Scrip surveyed industry leaders on the impacts for biopharma.
Finance Watch: Restructurings, Layoffs Reflect Ongoing Uncertainty In Biotech
Sio Gene, Genocea, Solid Biosciences, Saniona and Black Diamond join First Wave, Zosano, Vallon, Finch, Magenta, ProQR and Imara on the growing list of biopharma firms reducing headcount to make their cash last until valuations return to a level that may support new fundraising.
Korean COVID-19 Contenders Still Racing Toward Finish Line
Hyundai Bioscience’s niclosamide-based oral antiviral moves into Phase II, joining other Korean COVID-19 treatment candidates in the pivotal trial stages, while SK Bioscience’s Phase III recombinant protein vaccine gears up for global market entry.
- Large Molecule
- Other Names / Subsidiaries
- AzurRx BioPharma Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.